抗體片段市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Antibody Fragments Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月01日 | 出版商:

Global Market Insights Inc. | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球抗體片段市場價值為 73 億美元，預計 2024 年至 2032 年複合年成長率為 5.6%。它們經過專門設計，保留其親代抗體的結合特異性，同時提供獨特的特性，使它們適合整個抗體效果較差的應用。市場成長的主要驅動力之一是對標靶治療的需求不斷成長。個人化醫療的興起導致人們對提供高特異性的生物療法越來越感興趣。

抗體片段特別適合這些標靶治療，特別是在腫瘤學和免疫學領域，因為它們能夠針對特定抗原相互作用進行客製化。市場可依特異性分類，分為單株抗體和多株抗體。單株抗體類別包括針對特定治療用途客製化的各種產品。相較之下，多克隆抗體片段具有不同的產品，旨在解決一系列健康問題。

到 2032 年，單株抗體領域預計將達到 75 億美元，反映了該領域的持續創新。依類型分析市場，抗體片段又分為FAB、scFv、sdAb等類型。 2023 年，僅單鏈可變片段(scFv) 片段就佔23 億美元。治療。它們較小的尺寸使它們能夠接近具有挑戰性的目標，例如位於組織深處或較大抗體可能無法有效到達的特定微環境中的腫瘤細胞。到2020 年將達到40 億美元。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	73 億美元
預測值	117 億美元
複合年成長率	5.6%

該地區是全球癌症發病率最高的地區之一，這推動了對創新癌症療法以及抗體片段的需求。此外，美國眾多領先的生物技術和製藥公司支持這些療法的開發和商業化，進一步推動市場成長。隨著對個人化和標靶治療的需求持續成長，抗體片段市場預計將在未來幾年取得重大進展和擴張。

產業生態系統分析
產業影響力
- 成長動力
  - 標靶治療的需求不斷成長
  - 癌症盛行率不斷上升
  - 生物技術和基因工程的進展
  - 法規核准的成長
- 產業陷阱與挑戰
  - 與單鏈可變片段穩定性相關的擔憂
  - 開發成本高
成長潛力分析
技術景觀
監管環境
未來市場趨勢
波特的分析
管道分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按具體情況，2021 - 2032 年

主要趨勢
單株抗體
- Praxbind（伊達魯珠單抗）
- 雷珠單抗（Lucentis）
- 聚乙二醇賽妥珠單抗（Cimzia）
- 碘 (I 311) 美妥昔單抗/利卡汀
- Beovu（Brolucizumab-dll）
- Cablivi（Caplacizumab-yhdp）
- 博納吐單抗
多株抗體抗體
- 克羅法布
- 阿納維普
- 阿納斯公司
- 七價肉毒桿菌抗毒素
- 數位綁定
- 數位工廠

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
FAB
短鏈病毒
史達布
其他類型

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
癌症
免疫缺陷
其他應用

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AbbVie Inc.
Amgen
AstraZeneca
BioNTech
Bristol-Myers Squibb Company
Eli Lilly and Company
Genentech, Inc.
Johnson & Johnson
Merck & Co.
MorphoSys
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Company Limited
UCB Pharma

簡介目錄

Product Code: 11679

The Global Antibody Fragments Market was valued at USD 7.3 billion in 2023 and is anticipated to grow at 5.6% CAGR from 2024 to 2032. Antibody fragments are smaller components derived from full-length monoclonal antibodies. They are specifically designed to retain the binding specificity of their parent antibodies while offering unique properties that make them suitable for applications where whole antibodies may be less effective. One of the primary drivers of market growth is the increasing demand for targeted therapies. The rise of personalized medicine has led to a growing interest in biologic therapies that provide high specificity.

Antibody fragments are particularly well-suited for these targeted therapies, especially in oncology and immunology, due to their ability to be tailored for specific antigen interactions. The market can be categorized based on specificity, dividing it into monoclonal antibodies and polyclonal antibodies. The monoclonal antibody category includes various products tailored for specific therapeutic uses. In contrast, the polyclonal antibody segment features different products designed to address a range of health concerns.

The monoclonal antibody segment is projected to reach USD 7.5 billion by 2032, reflecting the ongoing innovation in this area. When analyzing the market by type, antibody fragments are further classified into FAB, scFv, sdAb, and other types. The single-chain variable fragment (scFv) segment alone accounted for USD 2.3 billion in 2023. The growing prevalence of cancer significantly contributes to the success of the scFv segment, as these fragments are increasingly used in targeted cancer therapies. Their smaller size enables them to access challenging targets, such as tumor cells located deep within tissues or in specific microenvironments that larger antibodies may not reach effectively.In the United States, the antibody fragments market is assumed to expand significantly, reaching USD 4 billion by 2032.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$7.3 Billion
Forecast Value	$11.7 Billion
CAGR	5.6%

The region has one of the highest cancer rates globally, which drives the demand for innovative cancer therapies and, consequently, antibody fragments. Additionally, numerous leading biotechnology and pharmaceutical companies in the U.S. support the development and commercialization of these therapies, further propelling market growth. As the demand for personalized and targeted treatments continues to rise, the antibody fragments market is poised for significant advancements and expansion in the coming years.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for targeted therapies
  - 3.2.1.2 Growing prevalence of cancer
  - 3.2.1.3 Advances in biotechnology and genetic engineering
  - 3.2.1.4 Growth in regulatory approvals
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Concerns related to stability in single-chain variable fragments
  - 3.2.2.2 High development cost
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Regulatory landscape
3.6 Future market trends
3.7 Porter's analysis
3.8 Pipeline analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Specificity, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Monoclonal antibody
- 5.2.1 Praxbind (Idarucizumab)
- 5.2.2 Ranibizumab (Lucentis)
- 5.2.3 Certolizumab pegol (Cimzia)
- 5.2.4 Iodine (I 311) metuximab/ licartin
- 5.2.5 Beovu (Brolucizumab-dbll)
- 5.2.6 Cablivi (Caplacizumab-yhdp)
- 5.2.7 Blinatumomab
5.3 Polyclonal antibody
- 5.3.1 Crofab
- 5.3.2 Anavip
- 5.3.3 Anascorp
- 5.3.4 Botulism antitoxin heptavalent
- 5.3.5 Digibind
- 5.3.6 Digifab

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 FAB
6.3 scfv
6.4 sdab
6.5 Other types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Cancer
7.3 Immunodeficiency
7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa